erlotinib hydrochloride has been researched along with binimetinib in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (binimetinib) | Trials (binimetinib) | Recent Studies (post-2010) (binimetinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 166 | 32 | 164 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolan, PO; Brenan, L; Dusaj, N; Goodale, A; Johannessen, CM; Landau, DA; Piccioni, F; Schiffman, JS; Zviran, A | 1 |
| Antonia, SJ; Boyle, TA; Chiappori, AA; Creelan, BC; Gray, JE; Haura, EB; Kim, J; Neuger, A; Ozakinci, H; Saltos, AN; Sansil, S; Shafique, MR; Tanvetyanon, T; Ugrenovic-Petrovic, M | 1 |
1 trial(s) available for erlotinib hydrochloride and binimetinib
| Article | Year |
|---|---|
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras) | 2023 |
1 other study(ies) available for erlotinib hydrochloride and binimetinib
| Article | Year |
|---|---|
Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genetic Fitness; Genotype; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation | 2020 |